Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1992 Nov;36(11):2454–2457. doi: 10.1128/aac.36.11.2454

Activity of clarithromycin alone or in combination with other drugs for treatment of murine toxoplasmosis.

F G Araujo 1, P Prokocimer 1, T Lin 1, J S Remington 1
PMCID: PMC284352  PMID: 1489188

Abstract

The activity of the macrolide antibiotic clarithromycin was examined alone or in combination with other drugs for the treatment of acute or chronic infections with Toxoplasma gondii in mice. A dose of 300 mg of clarithromycin per kg per day administered alone for 10 days, beginning 24 hours after infection, protected 10 to 30% of mice infected with lethal inocula of tachyzoites or tissue cysts of different strains of T. gondii, including some strains isolated from patients with both AIDS and toxoplasmosis. Although clarithromycin was protective, a wide variation in its activity against different strains was observed. Survival of infected mice was increased significantly by treatment with clarithromycin in combination with pyrimethamine or with sulfadiazine. Treatment of chronically infected mice with clarithromycin at 300 mg/kg/day administered alone for 8 weeks resulted in significant reduction in the numbers of T. gondii cysts in their brains. The combination of clarithromycin and minocycline resulted in an activity against T. gondii cysts that was significantly greater than the activity of clarithromycin or minocycline administered alone. These results indicate a role for clarithromycin in the treatment of human toxoplasmosis, particularly when this antibiotic is used in combination with other drugs with activity against T. gondii.

Full text

PDF
2454

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Araujo F. G., Guptill D. R., Remington J. S. Azithromycin, a macrolide antibiotic with potent activity against Toxoplasma gondii. Antimicrob Agents Chemother. 1988 May;32(5):755–757. doi: 10.1128/aac.32.5.755. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Araujo F. G., Huskinson-Mark J., Gutteridge W. E., Remington J. S. In vitro and in vivo activities of the hydroxynaphthoquinone 566C80 against the cyst form of Toxoplasma gondii. Antimicrob Agents Chemother. 1992 Feb;36(2):326–330. doi: 10.1128/aac.36.2.326. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Araujo F. G., Huskinson J., Remington J. S. Remarkable in vitro and in vivo activities of the hydroxynaphthoquinone 566C80 against tachyzoites and tissue cysts of Toxoplasma gondii. Antimicrob Agents Chemother. 1991 Feb;35(2):293–299. doi: 10.1128/aac.35.2.293. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Araujo F. G., Prokocimer P., Remington J. S. Clarithromycin-minocycline is synergistic in a murine model of toxoplasmosis. J Infect Dis. 1992 Apr;165(4):788–788. doi: 10.1093/infdis/165.4.788. [DOI] [PubMed] [Google Scholar]
  5. Araujo F. G., Remington J. S. Synergistic activity of azithromycin and gamma interferon in murine toxoplasmosis. Antimicrob Agents Chemother. 1991 Aug;35(8):1672–1673. doi: 10.1128/aac.35.8.1672. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Araujo F. G., Shepard R. M., Remington J. S. In vivo activity of the macrolide antibiotics azithromycin, roxithromycin and spiramycin against Toxoplasma gondii. Eur J Clin Microbiol Infect Dis. 1991 Jun;10(6):519–524. doi: 10.1007/BF01963942. [DOI] [PubMed] [Google Scholar]
  7. Chang H. R., Pechère J. C. In vitro effects of four macrolides (roxithromycin, spiramycin, azithromycin [CP-62,993], and A-56268) on Toxoplasma gondii. Antimicrob Agents Chemother. 1988 Apr;32(4):524–529. doi: 10.1128/aac.32.4.524. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Chang H. R., Rudareanu F. C., Pechère J. C. Activity of A-56268 (TE-031), a new macrolide, against Toxoplasma gondii in mice. J Antimicrob Chemother. 1988 Sep;22(3):359–361. doi: 10.1093/jac/22.3.359. [DOI] [PubMed] [Google Scholar]
  9. Derouin F., Chastang C. Activity in vitro against Toxoplasma gondii of azithromycin and clarithromycin alone and with pyrimethamine. J Antimicrob Chemother. 1990 Apr;25(4):708–711. doi: 10.1093/jac/25.4.708. [DOI] [PubMed] [Google Scholar]
  10. Derouin F., Nalpas J., Chastang C. Mesure in vitro de l'effet inhibiteur de macrolides, lincosamides et synergestines sur la croissance de Toxoplasma gondii. Pathol Biol (Paris) 1988 Dec;36(10):1204–1210. [PubMed] [Google Scholar]
  11. Fernandez-Martin J., Leport C., Morlat P., Meyohas M. C., Chauvin J. P., Vilde J. L. Pyrimethamine-clarithromycin combination for therapy of acute Toxoplasma encephalitis in patients with AIDS. Antimicrob Agents Chemother. 1991 Oct;35(10):2049–2052. doi: 10.1128/aac.35.10.2049. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Huskinson-Mark J., Araujo F. G., Remington J. S. Evaluation of the effect of drugs on the cyst form of Toxoplasma gondii. J Infect Dis. 1991 Jul;164(1):170–171. doi: 10.1093/infdis/164.1.170. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES